dnm1 Antibody

What is DNM1 and why is it significant in neuroscience research?

DNM1 encodes dynamin 1, a 97.4 kDa GTPase protein crucial for synaptic vesicle endocytosis in neurons. This protein may also be known as EIEE31 or DNM . DNM1 has gained significant attention in neuroscience research because mutations in this gene are associated with developmental and epileptic encephalopathy (DEE), a severe neurodevelopmental disorder characterized by early-onset seizures and cognitive impairment . The G359A variant, identified in multiple DEE patients, resides in the middle domain and exerts a dominant-negative effect that impairs endocytosis, disrupting normal neuronal function .

What species reactivity should I expect from DNM1 antibodies?

Most commercially available DNM1 antibodies demonstrate reactivity with human, mouse, and rat samples . Some antibodies have also been reported to react with pig, chicken, and fish tissues . When selecting an antibody for your research, it is essential to verify the specific reactivity profile, especially if working with less common model organisms. For instance, Proteintech's 18205-1-AP antibody has been validated for human, mouse, and rat samples .

What is the subcellular localization pattern of DNM1 in neuronal cells?

DNM1 is predominantly expressed in neurons and localizes to presynaptic terminals where it functions in synaptic vesicle recycling. Immunofluorescence studies using Neuro-2a cells have successfully detected endogenous DNM1 . When visualizing DNM1 in brain tissue, both rat and mouse brain samples have shown positive immunohistochemical staining . The protein's localization pattern typically appears punctate in neuronal processes, reflecting its association with endocytic machinery.

What are the optimal conditions for using DNM1 antibodies across different applications?

Based on extensive validation data, here are the recommended conditions for working with DNM1 antibodies:

These conditions are based on data from Proteintech's 18205-1-AP antibody . It is crucial to titrate any antibody in your specific experimental system to determine optimal working conditions.

What antigen retrieval methods are most effective for DNM1 immunohistochemistry?

For optimal DNM1 detection in fixed tissue sections, TE buffer at pH 9.0 is the recommended antigen retrieval method . If this approach yields suboptimal results, an alternative method using citrate buffer at pH 6.0 can also be effective . The choice between these methods may depend on your specific tissue type, fixation protocol, and the particular epitope being targeted by the antibody. Always perform a systematic comparison of different antigen retrieval methods when optimizing IHC protocols for DNM1 detection.

How should DNM1 antibodies be stored and handled to maintain their activity?

For optimal preservation of antibody activity, store DNM1 antibodies at -20°C where they typically remain stable for one year after shipment . Many commercial preparations are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain stability . Contrary to common practice with antibodies, aliquoting is often unnecessary for -20°C storage of these formulations . Some smaller volume formulations (e.g., 20μl sizes) may contain 0.1% BSA as an additional stabilizer . Always refer to the manufacturer's specific storage recommendations for your particular antibody.

How can I validate DNM1 knockdown or knockout in experimental models?

A multi-modal approach to validating DNM1 knockdown or knockout is recommended:

• Protein expression analysis: Western blot using validated DNM1 antibodies (dilution 1:1000-1:6000) should detect a band at approximately 100 kDa in wild-type samples that is reduced or absent in knockdown/knockout models .

• mRNA quantification: The search results describe a study using RNA sequencing to quantify both endogenous DNM1 mRNA and exogenous, codon-optimized replacement DNM1 . This approach allowed researchers to determine that their knockdown reduced DNM1 mRNA by 22% across brain regions in their mouse model .

• Functional assessment: Since DNM1 is essential for endocytosis, measuring endocytic capacity using fluorescent transferrin uptake or FM dye uptake in neurons can provide functional validation.

• RNAi efficiency screening: When developing knockdown models, researchers have successfully used a dual luciferase assay to screen potential miRNA candidates targeting DNM1 . In this system, constructs containing DNM1 cDNA as the 3′ UTR of Renilla luciferase permit quantitative assessment of knockdown efficiency .

What gene therapy approaches are being developed for DNM1-related disorders?

Recent research has explored an innovative "knockdown-replace" gene therapy strategy for treating DNM1-related neurodevelopmental epilepsy:

• RNAi-mediated knockdown: After screening 17 potential miRNA candidates, researchers identified five effective constructs (mi249, mi1156, mi1505, mi1869, and mi2186) for DNM1 silencing . The lead candidate, mi1869, achieved more than 60% silencing of both human DNM1 and mouse Dnm1 .

• Concurrent replacement: Simultaneously with knockdown, an RNAi-resistant, codon-optimized DNM1 cDNA was delivered to restore normal protein function . This replacement DNA was engineered with wobble mutations in miRNA binding sites to prevent silencing by the co-delivered RNAi .

• Delivery system: An AAV9 vector system was developed containing both the U6 promoter-driven miRNA and a human synapsin 1 promoter-driven replacement cDNA for neuron-specific expression .

In a mouse model expressing the pathogenic G359A variant in GABAergic neurons (which normally exhibits growth delay and lethal seizures), this therapy showed promising results . Protein analysis showed that the replacement DNM1 was successfully expressed, with the total DNM1 in treated tissue reaching approximately 30% of untreated levels .

How can DNM1 mutations be studied in relation to neurological disorders?

Researchers have developed several approaches to study DNM1 mutations and their role in neurological disorders:

• Conditional knock-in models: The search results describe a conditional G359A/+ Dnm1 mouse model using a knockout-first approach with a gene trap cassette flanked by loxP sites engineered to carry the point mutation (c.1076G>C) in exon 8 . This approach allowed researchers to circumvent the poor husbandry and survival typically associated with heterozygous DNM1 mutants .

• Cell-type specific expression: By restricting expression of mutant DNM1 to GABAergic neurons, researchers were able to create a model that exhibits growth delay and lethal seizures evident by postnatal week three . This approach helps elucidate the cell-type specific contributions to disease pathology.

• Comparative analysis: Studying different DNM1 variants (such as G359A and Ftfl) that map to the same domain but may have different molecular consequences provides insights into structure-function relationships and genotype-phenotype correlations .

What are common issues in DNM1 Western blotting and how can they be resolved?

When performing Western blots for DNM1, researchers may encounter several challenges:

• Weak or no signal:

  • Ensure you're using appropriate tissue; mouse brain tissue shows strong endogenous expression

  • Optimize antibody concentration within the recommended 1:1000-1:6000 range

  • Consider longer exposure times or more sensitive detection methods

  • Verify protein extraction protocol is suitable for membrane-associated proteins

• Multiple bands or unexpected band size:

  • The expected molecular weight for DNM1 is approximately 96-100 kDa

  • Multiple bands might represent isoforms (such as Dnm1a and Dnm1b mentioned in the research)

  • Validate specificity using DNM1 knockdown samples as negative controls

  • Consider using fresh samples to minimize degradation products

• High background:

  • Increase blocking time or concentration

  • Use more stringent washing conditions

  • Further dilute primary antibody while staying within recommended range

  • Try alternative blocking agents (BSA vs. milk)

How can I optimize immunohistochemical detection of DNM1 in brain tissue?

For optimal IHC detection of DNM1 in brain tissue:

• Tissue preparation: Both rat and mouse brain tissues have shown positive IHC results with DNM1 antibodies . Proper fixation is critical; overfixation can mask epitopes.

• Antigen retrieval: Use TE buffer at pH 9.0 as the primary method, with citrate buffer at pH 6.0 as an alternative if needed . Optimize retrieval time and temperature for your specific tissue preparation.

• Antibody dilution: Begin with a mid-range dilution (e.g., 1:250) from the recommended 1:50-1:500 range and adjust based on signal-to-noise ratio .

• Signal enhancement: For weak signals, consider using polymeric detection systems or tyramide signal amplification.

• Controls: Always include positive control tissue (brain) and negative controls (either no primary antibody or tissue known to lack DNM1 expression).

How can I distinguish between wild-type and mutant DNM1 in experimental models?

Differentiating between wild-type and mutant DNM1 in experimental models requires strategic approaches:

• Mutation-specific antibodies: While not mentioned in the search results, antibodies raised against specific mutant epitopes could theoretically differentiate mutant from wild-type protein.

• Tagged constructs: The research described using a V5-tagged, codon-optimized DNM1 for replacement therapy, which allowed differentiation from endogenous protein using tag-specific antibodies .

• RNA analysis: The researchers performed RNA sequencing to distinguish between endogenous Dnm1 mRNA and the exogenous, codon-optimized replacement . This approach revealed that the replacement DNM1 was expressed at approximately 5.9% of endogenous levels .

• Functional assays: Since mutations like G359A impair endocytosis, functional assays that measure endocytic capacity can indirectly distinguish mutant activity from wild-type.

• Protein expression analysis: Western blotting showed that despite lower mRNA levels, the codon-optimized replacement DNM1 protein was robustly expressed, reaching almost 30% of untreated levels after normalization . This demonstrates the importance of assessing both mRNA and protein levels when evaluating expression systems.

What is known about the relationship between DNM1 and nicotine dependence?

An intriguing research direction involves the relationship between DNM1 and nicotine dependence. Studies have shown that DNM1 expression is significantly modulated by nicotine in animal models . Researchers have investigated potential genetic associations by genotyping seven single-nucleotide polymorphisms (SNPs) within the DNM1 gene in 602 nuclear families of African-American or European-American origin . Individual SNP-based association analysis revealed a significant association of SNP rs3003609 with Smoking Quantity and Heaviness of Smoking Index in the European-American sample . This suggests DNM1 may play a role in the neurobiological mechanisms underlying nicotine dependence, possibly through its function in synaptic vesicle recycling and neurotransmitter release.

How can multi-omics approaches enhance our understanding of DNM1 function in health and disease?

While not explicitly covered in the search results, integrating proteomics, transcriptomics, and functional studies provides comprehensive insights into DNM1 biology:

• Transcriptomics: RNA sequencing can identify differential expression patterns of DNM1 isoforms (such as Dnm1a and Dnm1b) across tissues, developmental stages, or disease states .

• Proteomics: Mass spectrometry-based approaches can identify DNM1 interaction partners and post-translational modifications that regulate its function.

• Functional genomics: The knockdown-replace strategy described in the research represents an innovative functional genomics approach that could be applied to study other DNM1 variants or related proteins.

• Systems biology: Integrating these multi-omics datasets can reveal networks of genes and proteins that function with DNM1 in normal physiology and disease pathology.

By employing these complementary approaches, researchers can develop a more complete understanding of DNM1's role in neuronal function and how its dysfunction contributes to neurodevelopmental disorders.